1.	A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181114, NCT00428220
2.	Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 06-248, NCT00438256
3.	Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 00001597, NCT00735306
4.	Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-375, NCT00889187
5.	Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-114, NCT00948688
6.	Phase II Study of Postoperative Cisplatin, Interferon alfa, Fluorouracil, and Concurrent Radiotherapy in Patients With Previously Resected Pancreatic Adenocarcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MDA-ID-02040, NCT00068575
7.	Phase II Pilot Study of Neoadjuvant Chemoradiotherapy and Interferon alfa in Patients With Unresectable Locally Advanced Adenocarcinoma of the Pancreas Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UMN-2004LS060, UMN-2743RO, NCT00262951
8.	Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12095B, NCT00203892
9.	Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-Metastatic, Post-Resection Pancreas Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GI-4000-02, NCT00300950
10.	A Trial of Chemo & Radiation Therapy for Pancreatic Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: UM200602, NCT00424827
11.	Neoadjuvant Gemcitabine, Oxaliplatin, and Radiation Therapy for Pancreatic Cancer Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J-0686, NA_00003461, NCT00426738
12.	Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
13.	Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2006.025, NCT00456599
14.	Phase II Study of Neoadjuvant Erlotinib Hydrochloride in Patients With Resectable Intraductal Pancreatic Mucinous Neoplasm Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCIRVINE-UCI05-5-01, UCI05-5-01, NCT00482625
15.	Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreatic Adenocarcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-07113, MSK IRB #07-113, NCT00536874
16.	Vaccine Study for Surgically Resected Pancreatic Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0205, OBA#0701-829, NCT00569387
17.	Phase II Study of Induction Chemotherapy Comprising Gemcitabine Hydrochloride, Docetaxel, and Capecitabine and Neoadjuvant Chemoradiotherapy Comprising Capecitabine, Oxaliplatin, and Intensity-Modulated Radiotherapy Followed By Surgical Resection and Adjuvant Chemotherapy in Patients With Resectable, Localized Adenocarcinoma of the Pancreas Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: FHCRC-6511, 6511, UWCC-UW-6511, UWCC-07-7286-H/B, NCT00609336
18.	Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0305, OBA#0704-844, NCT00614601
19.	A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 02-0580, NCT00660699
20.	Phase II Study of Neoadjuvant and Adjuvant Gemcitabine Hydrochloride and Erlotinib Hydrochloride in Patients With Resectable Adenocarcinoma of the Pancreas Undergoing Pancreatectomy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ACOSOG-Z5041, Z5041, NCT00733746
21.	Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0459, NCT00766636
22.	Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-15587, IST 14091, IRB 107420, NCT00833859
23.	A Study of 7 Day Eroltinib Before Surgery Followed by After Surgery Erlotinib-gemcitabine in Patients With Pancreatic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 19 to 80 Sponsor: Other Protocol IDs: F080718006, NCT00841035
24.	A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: Adjuvant GTX Mar2009, AAAB4460, NCT00882310
25.	Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J-0534B, NA_00025965, NCT00962520